Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Their tumors are also mismatch repair proficient (MMRp)/microsatellite stable (MSS). MMRp/MMS means that their cells are working normally to repair any mistakes made during cell division.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
This purpose of this study is to assess two interventions to improve cancer care for older adults with cancer. Patients will be randomly assigned to one of the two interventions, which each consist of four surveys, five telephone sessions, and four subsequent "booster" calls with a licensed mental health counselor. The five telephone sessions each last about 45-60 minutes; the booster calls each last approximately 20-30 minutes. These surveys will include questions about each patient's illness, quality of life, depression, anxiety, and attitudes about aging and can be done via computer or over the phone. Patients will be compensated for their participation.
Researchers want to see if adding zanidatamab to standard treatment works well against biliary tract cancer. The people in this study have biliary tract cancer that has spread or cannot be removed with surgery. In addition, their cancers make a protein called HER2.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).
